The shortage timeline
Tirzepatide is the active ingredient in Eli Lilly's Mounjaro (Type 2 diabetes) and Zepbound (chronic weight management). It's a dual GIP/GLP-1 receptor agonist and one of the most-prescribed medications in the United States since 2023.
From late 2022 through October 2024, FDA listed tirzepatide on its drug shortage list. While a drug is on the shortage list, 503A and 503B compounding pharmacies are permitted under federal law to compound a copy of that drug — a narrow exception to the general rule that compounders cannot copy commercially available FDA-approved drugs. That exception was the legal basis for the explosion of compounded-tirzepatide telehealth platforms in 2023-2024.
| Date | Status | Practical effect |
|---|---|---|
| Late 2022 | Tirzepatide added to FDA shortage list | Compounders permitted to compound copies |
| 2023-2024 | Compounded tirzepatide widely available via telehealth | Lower-cost access surged |
| October 2024 | FDA declares shortage resolved | Compounding-copy exception begins to wind down |
| Late 2024 - early 2025 | Transition period with litigation | Some compounders contested the resolution |
| 2025-2026 | 503A patient-specific compounding remains, copy-of-FDA-drug pathway closed | Access landscape narrows but does not close entirely |
The 2024-2025 transition
FDA declared the tirzepatide shortage resolved in October 2024. Under the federal compounding statute, the resolution of a shortage closes the pathway by which compounders can produce copies of an FDA-approved drug. The compounding-pharmacy industry contested this through litigation, and the resolution and transition period extended into 2025.
Where things landed: 503B outsourcing facilities and 503A pharmacies generally cannot compound mass-produced "copy" tirzepatide. What remains is the narrower 503A pathway — patient-specific compounding under prescription, where the compound is materially different from the commercial product (different dosing, additional ingredient, documented clinical need). This is significantly more constrained than what existed in 2023-2024.
After October 2024, compounded tirzepatide isn't a price-arbitrage product anymore. It's a clinically specific compound — or it isn't a defensible prescription.
What state pharmacy boards do
State pharmacy boards regulate the pharmacies operating in their state and the pharmacies that ship into their state. After the shortage resolved, state pharmacy boards interpreted the federal change differently — most followed FDA's position immediately; some allowed brief transition periods; a few took stricter or looser positions on what counts as a permissible patient-specific compound.
The practical result for a patient: the legality of receiving compounded tirzepatide in 2026 depends on the specific compounding rationale, the pharmacy's licensure footprint, and the prescribing physician's state. Generic "compounded tirzepatide for everyone" telehealth marketing should be read carefully — the underlying legal pathway is much narrower than it was 18 months ago.
What's still accessible
What remains accessible in 2026: FDA-approved tirzepatide products (Mounjaro, Zepbound) through retail pharmacies, on the manufacturer's pricing model. Patient-specific 503A compounded tirzepatide where there's a documented clinical reason — typically a different concentration, an alternate route, or additional active ingredients — and where the pharmacy is comfortable with the compounding rationale.
What's broadly no longer accessible: high-volume mass-produced compounded tirzepatide marketed at "shortage-era" prices, sold without specific clinical justification. Telehealth platforms that continued operating on this model into 2026 are operating against FDA's stated position.
For more on the broader peptide-legality landscape, see are compounded peptides legal under the FDA and peptides legal by state, 2026.
Questions worth asking your provider
- What is the specific compounding rationale for the tirzepatide you'd be prescribing — concentration, route, additional ingredient?
- Is the pharmacy a 503A facility, and is it registered to ship into my state?
- How does the pricing compare to the FDA-approved product on a like-for-like dose?
- What happens if the compounding rationale is challenged — is the pharmacy prepared for that?
- For weight management specifically: does the prescriber consider the FDA-approved Zepbound product as a default, with compounding as a clinically driven alternative?
Sources